Teaching Staff
 
HONG, Yanjun - Research Assistant Professor
洪燕君

Educational Background
  • B.Sc., Zhejiang University, China
  • Ph.D., Zhejiang University, China
  • Postdoctoral: National University of Singapore, Singapore

Current Research Interests
  • Mass spectrometry-based metabolomics in environmental toxicity and clinical research; Metabolic bioactivation of environmental pollutants.

Contacts

Selected Publications
  1. G. Cao, D. Ruan, Z. Chen, Y. Hong, Z. Cai, “Recent developments and applications of mass spectrometry for the quality and safety assessment of cooking oil”, TrAC, in press (2017).
  2. L. J. Liu, W. Wang, S. Y. Huang, Y. Hong, J. Tian, Z. Cai, H. M. Wang, D. L. Ma, C. H. Leung, “Inhibition of the Ras/Raf Interaction and Repression of Renal Cancer Xenografts In Vivo by an Enantiomeric Iridium (III) Metal-Based Compound”, Chem. Sci., 8, 4756-4763 (2017).
  3. E. J. Y. Cheong, J. J. N. Goh, Y. Hong, G. Venkatesan, Y. Liu, G. N. C. Chiu, P. Kojodjojo and E. C. Y. Chan, “Application of static modeling in the prediction of in vivo drug-drug interactions between rivaroxaban and anti-arrhythmic agents based on in vitro inhibition studies”, Drug Metab. Dispos., 135, 12-21 (2017).
  4. A. Karkhanis, Y. Hong, E. C. Y. Chan, “Inhibition and Inactivation of Human CYP2J2: Implications in Cardiac Pathophysiology and Opportunities in Cancer Therapy”, Biochem Pharmacol., in press (2017).
  5. Y. Hong, Y. M. F. Chia, R. H. Yeo, G. Venkatesan, S. K. Koh, C. L. L. Chai, L. Zhou, P. Kojodjojo and E. C. Y. Chan, “Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-desbutyl Dronedarone”, Mol. Pharmacol., 89(1), 1-13 (2015).
  6. Y. Hong, K. Esuvaranathan, K. K. Pasikanti, E. C. Y. Chan, “Metabonomic Diagnosis of Bladder Cancer - What are the Advantages and Considerations?”, Bioanalysis, 7(21), 2727-2729 (2015).
  7. T. P. Lim, Y. Cai, Y. J. Hong, E. C. Y. Chan and et. al., “In-vitro Pharmacodynamics of Various Antibiotics in Combination Against Extensively Drug-resistant Klebsiella Pneumoniae”, Antimicrob. Agents Chemother., 59(5), 2515-2524 (2015).
  8. E. C. Y. Chan, K. K. Pasikanti, Y.  Hong, P. Ho and et.al., “Metabonomic Profiling of Bladder Cancer”, J. Proteome Res., 14(2), 587-602 (2014).
  9. P. Bahety, Y. M. Tan, Y. Hong, L. Zhang, E. C. Y. Chan, P. L. R. Ee, “Metabotyping of Docosahexaenoic Acid-treated Alzheimer’s Disease Cell Model”, PloS one., 9, e90123 (2014). 
  10. K. K. Pasikanti, K. Esuvaranathan, Y. Hong, P. C. Ho, R. Mahendran, N. M. L. Raman, E. C. Y. Chan, “Urinary Metabotyping of Bladder Cancer Using Two-dimensional Gas Chromatography Time-of-flight Mass Spectrometry”, J. Proteome Res., 12(9), 3865-3873 (2013).
  11. T. Liu, Y. Hong, P. Huang, Z. H. Li, J. Y. Hong, S. Zeng, M. Y. Zheng, S. Q. Chen, “An Investigation of the Catalytic Activity of CYP2A134 with Coumarin and Polymorphisms of CYP2A13 in a Chinese Han Population”, Drug Metab. Dispos., 40(5), 847-851(2012).
  12. L. S. Yu, Y. Hong, L. Li, Y. X. Jin, M. Y. Zheng, H. L. Jiang, S. Zeng, “Enantioselective Drug-protein Interaction between Mexiletine and Plasma Protein”, J. Pharm. Pharmacol., 64(6), 792-801 (2012).